AstraZeneca stock bounded into a buy zone Thursday after sales of its cancer drugs beat Wall Street's expectations by about 5 ...

The Anglo-Swedish drugmaker is looking to new launches, including a blood pressure drug, to offset patent expiries for ...

Eli Lilly and Novo Nordisk will lower prices for GLP-1 receptor agonists, aligning with the Most Favored Nation executive ...

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (AZN) today announces the launch of AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access ...

In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based ...

ASTRAZENECA delivered better-than-expected third quarter earnings and retained its full-year forecasts on Thursday, with strong sales of its blockbuster cancer and cardiovascular drugs.

Trump announces deal with Eli Lilly, Novo Nordisk to lower cost of GLP-1 weight loss drugs Wegovy, Zepbound. Here's what to ...

Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some ...

Eli Lilly and Novo Nordisk agree to expand access and cut prices for Zepbound and Wegovy • Medicare to begin covering obesity ...

Access to the drugs has been a consistent problem for patients because of their cost — around $500 a month for higher doses — ...